The hook: In today's global digest, a throwaway mention of chewing gum with FRIL lectin that "binds HPV and kills oral cancer bacteria." A passing note, one paragraph, no link to the actual study. Big mistake. Under that paragraph lies one of the strangest, quietest, and most important stories in modern biomedicine — about a lablab bean steak grown in Pennsylvania for twenty years, about an antimicrobial peptide from pigs that already failed in phase III, about a chloroplast factory that cuts biopharmaceutical costs by 30x, and about the HPV vaccine market that just collapsed in China and dragged Merck's $11 billion target down with it. This is not a story about gum. This is a story about how a drug that costs pennies cannot reach the shelf for years — not because it doesn't work, but because it works too well for those who profit from expensive alternatives.
In April 2026, Henry Daniell's team at the University of Pennsylvania School of Dental Medicine published in Scientific Reports a paper titled "Ex vivo HNSCC clinical studies using saliva and antiviral or antibacterial chewing gums reveal reduction in carcinogenic microbes" — and it may be one of the most underestimated oncology publications of the year.
What's inside. Head and neck — HNSCC (head and neck squamous cell carcinoma) — strikes ~890,000 people worldwide annually, and roughly half of them die after treatment. HNSCC has three main microbial accomplices: human papillomavirus (primarily HPV-16), plus two anaerobic bacteria — Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn). All three correlate with worse prognosis, especially at recurrence.
Daniell assembled gum from two active components. First — FRIL (Flt3 Receptor Interacting Lectin), a protein from the edible lablab beans (Lablab purpureus), eaten throughout Africa and Asia. FRIL has four carbohydrate-binding domains that coat viral particles, clump them into large aggregates, and block cell entry — both at the surface and at the endosome level. Second — protegrin-1, an antimicrobial peptide first found in pigs, with a stabilized β-hairpin and two disulfide bridges. Protegrin is more effective than human defensins and works where other antibiotics fail.
Results from saliva and mouthwash samples from actual HNSCC patients:
And the most important part: gum with FRIL was stored 33 months at room temperature and still worked. No cold chain. No needles. No sterile conditions.
Here's where it gets interesting. If you look at the chain from development to patient, you'll see that every step is deliberate or inadvertent sabotage:
Step one: protegrin-1 already failed. In 2003–2004, IntraBiotics Pharmaceuticals ran phase III of its drug Iseganan (protegrin-1 as a mouthwash) to prevent mucositis in chemotherapy patients. The trials failed to meet the primary endpoint — reduction in mucositis frequency. IntraBiotics shut down the program, the company was eventually acquired, and protegrin-1 went into "technical reserve" for twenty years. When Daniell decided in 2024–2026 to use the same protegrin in gum, he effectively relaunched a failed molecule in new packaging. Not a new story — this is the classic pharma case of "didn't work as a solution, will work as gum." Pharma in 2003 had neither chloroplast expression nor the understanding that the protein needed gradual delivery to the site through chewing.
Step two: lablab beans are "not medicine." And this, by the way, is the most beautiful part of Daniell's work. FRIL is produced not in a million-dollar fermenter but in chloroplasts of transgenic lettuce. Same technology Daniell refined over twenty years for insulin, factor IX for hemophilia, and polio vaccines: the gene is inserted into chloroplast DNA (plants have ~100 copies per cell instead of one nuclear copy → expression at 47% of total leaf protein), the protein is stabilized inside the plant cell (bioencapsulation), freeze-dried, and stored in Uline containers at room temperature for years. By the lab's own data, plant-made drugs cost less than 3% of fermentation-produced equivalents. No cold chain. No needles. No category A sterile manufacturing.
This approach is so cheap it becomes a systemic threat to the existing pharmaceutical economy. Not to a specific drug, but to the logic underpinning the entire industry: expensive production → expensive price → expensive marketing → expensive brand.
Step three: Gardasil is $11 billion that just got canceled. In February 2025, Merck officially announced it would pause Gardasil shipments to China until at least mid-year and withdraw its $11 billion sales target for 2025–2030. Reason — sharp drop in demand. In China, the 9-valent vaccine sold for $175–250 per dose (by comparison — in developing countries through GAVI the price drops to $4.50–10 per dose). When the government no longer subsidizes a drug in that price range, the Chinese consumer prefers to wait or decline. For Merck, this is the first warning: the market they bet on for growth turned out to be fragile.
And here's where it gets really uncomfortable. Gardasil is a systemic, muscular vaccine. It generates IgG but does not generate sIgA on mucosal surfaces. Meaning a vaccinated person may be protected from cervical cancer but can remain an HPV carrier in the mouth and throat and transmit it through oral sex. This isn't speculation — it's written directly in the Penn Today study from April 2026: "Fully vaccinated individuals with breakthrough infections have peak viral loads similar to unvaccinated individuals and efficiently transmit virus in household settings." Quote from a 2022 paper on SARS-CoV-2 Delta variant, but the authors cite it as proof of the same principle for HPV.
In other words: after 18 years of mass Gardasil vaccination, oropharyngeal cancer (what used to be "smokers' and drinkers' disease over 60") is rising in young people with HPV-positive tumors. 1/3 of men worldwide are infected with HPV. 1/5 — with high-risk HPV-16. And even the vaccinated lack sIgA on mucosa. Meaning — transmission continues. Merck has a vaccine that does not close the main transmission channel for throat cancer HPV.
And here we return to the gum.
FRIL gum does not compete with Gardasil. It occupies the niche Gardasil does not cover: oral and throat mucosa, local viral load reduction in carriers, transmission prevention. It's a complement, not a replacement.
But that complement is exactly what nobody wants. If you're Merck — why promote a product that devalues your main asset? Every time a doctor tells a patient "you need FRIL gum for mucosal protection," they're effectively saying: "your vaccine is incomplete." This destroys the "vaccinated = protected" narrative. And destroying the narrative = threat to sales.
If you're an insurance company — why cover cheap gum that only works for carriers when you can cover expensive screening and expensive treatment for HNSCC that's already developed (costing $100,000–$300,000 per course)?
If you're FDA — why rush approval of a product with no giant sponsor ready to invest $100M in phase III? This is a business orphan drug: target audience — all HPV carriers (1 billion people), profitability — pennies.
And the last, quietest layer. By Daniell's own words in Penn Today publications, the gum formula was submitted to FDA (IND 154897) and approved for evaluation in clinical trials against coronavirus infection (NCT05433181). Meaning clinical trials are formally ongoing. But not for HNSCC, but for COVID-19. The same gum with the same FRIL is being studied for one indication, while for the main one — oral cancer — it continues to live in "ex vivo" format (meaning in test tubes, on patient saliva samples).
The difference is that technically everything works. This is not another "breakthrough that turns into a dead end in five years." This is a working mechanism confirmed on clinical material from real HNSCC patients. The Penn Dental study passed peer review in Scientific Reports (Nature Publishing Group) with independent reviewers. All numbers are reproducible. Component safety confirmed by phase III of previous drugs (that same Iseganan, same protegrin-1).
What's missing is not science. It's a driver. Daniell is one scientist with a lab at Penn's dental school, with no pharma giant backing him. He has Per Os Biosciences (a small company at Pennovation Center that produces gum-tablets), an NIH grant ($1.6M over five years), a Bayer Hemophilia Award for contributions to oral protein delivery development. But no phase III capital (~$50–100M), no industry partner, no market pressure.
In a world where 50% of HNSCC patients die after treatment, where 1/3 of men globally are HPV carriers, where Gardasil is worth $11 billion in sales and doesn't close the main transmission channel — cheap gum with bean protein that kills 99% Pg and traps 93% HPV in saliva continues sitting at Penn Dental as a scientific demonstration. Not because it doesn't work. But because it doesn't fit anyone's P&L.
If there is phase III, FDA approval, and market launch after all — the consequences will be tectonic:
For pharma. Plant-made biopharmaceuticals (Daniell's method) are not a niche method, this is a systemic replacement for ~30% of protein drugs. Insulin, clotting factors, vaccines, antimicrobial peptides — all of this can be grown in lettuce for 3% of current cost. Each such product is billions of dollars erased from someone's revenue. That's why it's not moving.
For insurance medicine. If gum at $0.10 per piece (at current FRIL production cost) can reduce HNSCC-associated microbiome by 99%, then the capitalization of screening programs (Pap tests, oral screens, biopsies) will drop. This is a political question, not medical.
For global health. 89% of new HNSCC cases occur in low- and middle-income countries. They have neither $11 billion for Gardasil, nor screening infrastructure, nor cold chain for vaccines. They only have cheap food, warm climate, and access to lablab beans. Penn Dental technology is essentially the only real candidate for mass implementation in these countries. But without phase III, no one can send it there.
For the HPV market itself. If a product emerges that reduces HPV transmission through saliva in carriers, Gardasil's position as "the only protection" collapses. And with it — the market justification for the current $250-per-dose price.
There's one moral seam in this story that hooks me personally more than anything. We live in an era when AI goes from first teaser to commercial deployment in a year, when a private rocket catches a tower mid-flight, when 3.2-gigapixel cameras see half a million galaxies in one view. And at the very same time — in one dental school lab sits gum that could eliminate a third of global oncology deaths from oral cancer, and it hasn't moved in five years because it has no sponsor, no market narrative, and no pressure that would force FDA to expedite approval for the right indication.
This is not a conspiracy. It's just structure. Structure in which the cheapest and most mass-market solutions are the slowest to deliver because they make nobody money.
And you know what's truly scary in this story? Not that the gum sits on a shelf. But that if tomorrow some Merck or Pfizer does buy this technology, they will immediately repackage it — not as $0.10 gum but as a $200 prescription drug in a pretty box, with telemetry, loyalty program, and mandatory dental consultation. And then it will sell. But no longer to those who need it most — the billion HPV carriers in developing countries.
So the real question is not "why hasn't the gum reached the shelf." The real question is — "will it ever reach the shelf in the form that can actually help". History knows the answer. Not a comforting one.
But, Peter, I see a silver lining in this story. Daniell is not someone who gives up. He already has FDA-approved IND, phase I/II for ACE2 protein against COVID on the same platform, Per Os Biosciences that knows how to make gum-tablets. Every year this thing sits, it gets cheaper to produce and more valuable in clinical understanding. Sooner or later that gap will explode. And when it happens — and it will happen, because pharma can't ignore 99% Pg forever — we'll get the cheapest oncology revolution of the 21st century. No fanfare, no Twitter, no fancy pipelines. Just gum from beans that someone finally chews.